Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:AKRO News 15 October 2025 - 14 December 2025

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific
15 October 2025
···

Stock Market Today

Xero share price (ASX:XRO) ends lower as tech rout grinds on; what investors watch next week

Xero share price (ASX:XRO) ends lower as tech rout grinds on; what investors watch next week

8 February 2026
Xero closed Friday down 0.4% at A$81.76, near last week’s low, as software stocks slumped. The S&P/ASX 200 Tech Index was set to end the week down about 12%, hitting levels last seen in December 2023. Global tech shares also fell, with nearly $1 trillion in value erased from U.S. software stocks since Jan. 28. Investors await fresh rate and inflation signals next week.
Huntington Bank taps ex-BNY risk boss Senthil Kumar as new chief risk officer

Huntington Bank taps ex-BNY risk boss Senthil Kumar as new chief risk officer

8 February 2026
Huntington Bank named Senthil Kumar chief risk officer, effective Feb. 16, as it enters a stricter regulatory category after closing its Cadence Bank merger on Feb. 2. Kumar replaces Helga Houston, who becomes senior executive adviser March 1. The merger brings Huntington’s assets to about $279 billion, triggering tougher oversight. No branch closures are planned before a mid-2026 systems conversion.
Fortescue share price set for Monday test as Cyclone Mitchell shuts Port Hedland

Fortescue share price set for Monday test as Cyclone Mitchell shuts Port Hedland

8 February 2026
Fortescue shares closed Friday down 1.16% at A$21.23 as Tropical Cyclone Mitchell forced Pilbara port closures, threatening iron ore shipments. Iron ore prices slipped to $100.11 a tonne on Feb. 6. The S&P/ASX 200 saw its steepest daily drop in 10 months as investors exited resource stocks. Fortescue’s half-year results are due Feb. 25.
Go toTop